As a CEO of Deep Longevity, which has just been acquired by Regent Pacific (HKEX: 0575) I now have to bee very careful about what I say about the company. I will not be able to provide any financial guidance, investment advice, or talk about anything that is not public knowledge already.
This announcement came on the second day of the largest conference on aging research and drug discovery in recorded history — 7th Aging Research and Drug Discovery (7th ARDD), and made quite a splash in the longevity biotechnology circles. …
Did you know that we are aging at the psychological level and there is a way to think, feel, and behave as a younger individual?
All the world’s a stage,
And all the men and women merely players;
They have their exits and their entrances,
And one man in his time plays many parts,
His acts being seven ages. At first, the infant,
Mewling and puking in the nurse’s arms.
Then the whining schoolboy, with his satchel
And shining morning face, creeping like snail
Unwillingly to school. And then the lover,
Sighing like furnace, with a woeful ballad
Made to his mistress’ eyebrow. Then a soldier,
Full of strange oaths and bearded like the pard,
Jealous in honour, sudden and quick in quarrel,
Seeking the bubble reputation
Even in the cannon’s mouth. And then the justice,
In fair round belly with good capon lined,
With eyes severe and beard of formal cut,
Full of wise saws and modern instances;
And so he plays his part. The sixth age shifts
Into the lean and slippered pantaloon,
With spectacles on nose and pouch on side;
His youthful hose, well saved, a world too wide
For his shrunk shank, and his big manly voice,
Turning again toward childish treble, pipes
And whistles in his sound. …
During our 5-year journey, we tried many things, made many mistakes, and got famous in several industries primarily due to our commitment to leadership in technology and open collaboration. We did not take an easy route, where you turn the idea into a business plan, hire several big names, and try to build a company that big pharma would buy. Instead, for 5 years we bootstrapped and hired predominantly technical talent through hackathons and competitions to work on the end-to-end drug discovery pipeline and harmonize, and annotate massive amounts of data to build the automated engine for drug discovery that currently surpasses everything out there. …
For the many experts in AI, pharma, and longevity industries who know our team well the recent announcement of our $37 million round may come as no surprise. We are the original inventors of some of the critical technologies that make it possible to identify and prioritize disease targets in very unique way, evaluate human relevance of disease models, validate these targets with novel chemistry, and predict the outcomes of the clinical trials outcomes. We were also the original inventor of the deep aging clocks that gradually learn human biology and can be retrained on diseases. And we started validating some of the super cool targets in oncology, fibrosis, and NASH. All this sounds too good to be true. To be honest, even I find some of the things we managed to achieve on the budget we had hard to believe, and I only wish to be able to publish the cool stuff once we get to the next level. …
9月10日，香港 — — AI药物研发公司Insilico Medicine日前完成了3700万美元的B轮融资，启明创投领投，斯道资本、F-Prime Capital、礼来亚洲基金、创新工场、百度风投、兰亭投资、BOLD Capital Partners等其他投资方（包括A轮投资方）跟投。
Insilico Medicine开发和验证了一套可供生成模型以及机器学习的算法，用来设计生成小分子靶向药物。同时公司还能通过其靶点发现平台找到在癌症、纤维化、NASH、免疫学和中枢神经系统疾病等方面的靶点。在商业模式上，Insilico Medicine通过与早期的生物技术公司以及大型生物制药公司的合作来推动数字时代医药行业的发展。
“我们很高兴能够领投Insilico Medicine的本轮融资，”启明创投主管合伙人梁颕宇（Nisa Leung）女士说，“Insilico是人工智能药物开发赛道的行业领导者，我们期待公司能利用其先进的技术缩短药物开发的时间，并且与启明创投的其他被投企业产生协同效应。”
Insilico Medicine与生物技术公司、制药公司和学术机构开展了密切的合作。自成立以来，该公司在专业期刊及人工智能会议上发表或联合发表了逾70篇论文。值得一提的是，Insilico Medicine最近在《自然》子刊Nature Biotechnology上发表最新研究论文，其主要内容是展示用生成模型以及增强学习算法设计出来小分子靶向药物，并且在细胞和动物模型上验证了设计出来的分子的活性和初步药代动力学特性。
Insilico Medicine是一家新兴人工智能公司，总部位于香港，并且在全球六个国家设有办公室。该公司致力于通过开发和应用下一代深度学习方法来改变制药行业，以实现药物发现和药物开发过程的每一步。Insilico Medicine持续与最具创新性的生物制药公司合作，开展与疾病相关的分析，以验证其解决方案并生成高质量的机器可学习的数据。
Tuesday, September 10, Hong Kong — Insilico Medicine, a pioneer in next-generation artificial intelligence technology for drug discovery, recently completes a $37 million funding round led by Qiming Venture Partners, joined by Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, BOLD Capital Partners, Oculus co-founder, Michael Antonov, Longevity Vision Fund, Juvenescence and other investors including series A investors.
The Series B funding will be used to commercialize the validated generative chemistry and target identification technology. The company will also build up a senior management team with the experience in the pharmaceutical industry, further develop its pipeline in cancer, fibrosis, NASH, immunology, and CNS for the purposes of partnering with the pharmaceutical companies on specific therapeutic programs. …
The Advent of Human Life Data Economics
Recent advances in artificial intelligence and precision medicine led to the emergence of new businesses that trade and process human health data. Most pharmaceutical companies are acquiring large volumes of clinical and other data for research and marketing purposes. However, there are few examples of companies turning this data into new therapeutic products and it is difficult to estimate the potential benefits stemming from a specific data type or a combination. …
There is no better feeling than being firmly convinced that you are doing the right thing in life. This is the comfort provided by most religions. But outside religion, given the multitude of career opportunities and decisions you make every day how do you know that you are maximizing your time on this planet.
In this short article on Forbes I present my personal view on how to maximize the time. With this mindset regardless of how much you work, it does not feel like work.
If you have a teenage offspring who does not know what carrier to chose in order to have a very satisfying life, please consider passing this article along. I wish I had a chance to read it 30 years ago but back then it was too early. Longevity biotechnology is a real thing now and there are credible business models emerging every day and funding is becoming more abundant. …
On Monday, February 4th, 2019 the Big Data Institute announced a new doctoral training program:
Insilico Medicine is happy to contribute to this wonderful initiative. The University of Oxford is considered to be #1 in the world in artificial intelligence and now we know why. They do accept only the best of the best students and focus on academic excellence.
We are happy to follow with a press release of our own.
Thursday, February 7, 2019 — Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, announces its partnership with a new Centre for Doctoral Training (CDT) at the University of Oxford, supported by EPSRC (The Engineering and Physical Sciences Research Council). …
I would like to congratulate our investors, friends, business partners, and fellow longevity biotechnology experts at Juvenescence on the first close of their series B. The company now raised over $100 million and turned into a household name in the longevity biotechnology community. Everyone aspires to work with Juvenescence and develop life-saving products together.
Here are the details from the press release on the Business Wire today:
January 16, 2019 03:00 AM Eastern Standard Time
DOUGLAS, Isle of Man — (BUSINESS WIRE) — Juvenescence Ltd, a biopharmaceutical company focused on modifying ageing and age-related disease, is pleased to announce the close of the first tranche of its Series B financing, in the amount of $46 million. Juvenescence intends to complete its $100 million Series B financing with the closing of a second tranche in Q1 2019. Juvenescence has now raised over $110 million in the past 15 months, which has enabled the rapid growth and development of the company’s team, its strategic relationships, and its pipeline of therapies. …